Quarterly ResultJul 29, 2026, 09:01 PM
Mesoblast Q4 Ryoncil Revenue $36M; Full Year $115M
AI Summary
Mesoblast reported strong financial and operational progress for the fourth fiscal quarter and full year ended June 30, 2026. Ryoncil net revenue for Q4 was US$36 million, contributing to a full-year revenue of US$115 million post-FDA approval, with US$103 million cash on hand. The company achieved its target of at least 300 patients in the pivotal Phase 3 trial for chronic low back pain and commenced a registration trial for Ryoncil in adults with SR-aGvHD. Additionally, Mesoblast received IND clearance for Ryoncil in Duchenne muscular dystrophy and acquired an exclusive worldwide license to a CAR technology platform.
Key Highlights
- Ryoncil net revenue for Q4 was US$36 million.
- Full-year Ryoncil net revenue reached US$115 million post-FDA approval.
- Mesoblast held US$103 million in cash as of June 30, 2026.
- Achieved target of at least 300 patients in pivotal Phase 3 trial for chronic low back pain.
- Commenced registration trial for Ryoncil in adults with steroid-refractory acute GvHD.
- Received IND clearance for Ryoncil in Duchenne muscular dystrophy in children.
- Acquired exclusive worldwide license to a CAR technology platform.
Price Impact
More from MESO